Drew Weissman of the Perelman School of Medicine commented on an announcement by Moderna Inc. that they have made progress on their mRNA-based coronavirus vaccine. “There are still many stages that need to be achieved,” cautioned Weissman, who developed and licensed the technique used in the research.